Ophirex Develops Potential Lifesaving Anti-Venom Pill Amid Rising Snakebite Fatalities
Ophirex, a Bay Area-based public benefit corporation, is advancing the development of an anti-venom pill named Varespladib, which could significantly improve survival rates for snakebite victims. This development comes in response to a notable increase in snakebite fatalities in California, where three deaths have been reported in just two months. The Centers for Disease Control and Prevention typically reports an average of five snakebite deaths annually across the United States. Varespladib works by neutralizing a key toxin present in 95% of snake species and is intended to be used alongside hospital-administered anti-venom treatments. The pill is particularly effective against common North American snakes, including several rattlesnake species and the Copperhead. Ophirex aims to secure FDA approval for human and canine use by late next year, with the goal of making the treatment accessible to backpackers and emergency personnel. 
